of PD [1, 2] . The most prevalent mutation in European populations, G2019S, is associated with approximately 3% of sporadic PD and 30-40% of familial PD cases among Ashkenazi Jews and North African Arabs [3, 4] . Patients with LRRK2 mutation exhibit late disease onset with symptoms indistinguishable from idiopathic PD patients, and are also responsive to L-dopa treatment. The pathology associated with LRRK2 mutations is heterogeneous. Most cases of PD associated with mutations in LRRK2 display Lewy body pathology in the brainstem and substantia nigra -the most common pathological presentation of subjects with mutations in LRRK2 [5, 6] . A small number of cases present with tau-positive neurofibrillary tangle pathology or with no visible inclusion pathology [5, 6] .
level GTPase activity [11, 12] . Studies of LRRK2 ROC protein, produced as recombinant protein, demonstrate that the ROC domain has the capacity to dimerize [13] . Studies of LRRK2 using transfected cells also suggest that the full-length protein also dimerizes [14] [15] [16] [17] . The MKKK domain shares homology with mixed lineage kinases, which regulate stress kinase cascades [18] . Multiple studies demonstrate that LRRK2 can autophosphorylate, although the amount of activity generated is low [19] [20] [21] . The G2019S LRRK2 mutation increases autophosphorylation activity [19] [20] [21] [22] [23] . Many other diseaselinked mutations also increase autophosphorylation, but the stimulation is less than for G2019S and does not occur with all disease-linked mutations. A number of putative targets of LRRK2 phosphorylation have been suggested, including E4-BP and moesin, but these results have yet to be confirmed by other groups [24, 25] .
Increasing evidence supports a putative link between LRRK2 function and the MAP kinase (MAPK) cascades. LRRK2 was recently shown to phosphorylate MKK3, -4, -6 and -7 [26] . We recently demonstrated that LRRK2 binds to MKK6, -3, and -7, and activates the p38 and c-jun NH2-terminal kinase (JNK) pathway [27] . Association of LRRK2 with MKKs stimulates expression and membrane translocation of these proteins, but does not strongly increase their phosphorylation. Localization of kinases is often facilitated by binding to scaffold proteins, which tether the kinases to particular membrane organelles and bring the kinases together with their substrates. Previous studies demonstrated that scaffold proteins are essential in the regulation of subcellular localization of stress kinase complexes. The JNK-interacting proteins (JIPs) are a group of scaffold proteins that play an important role in the regulation of MAPK signaling cascades [28] . JIP1-3 are known to regulate the specificity and localization of JNK pathway, while JIP4 is a specific scaffolding protein for the p38 pathway [28] [29] [30] . Given these data, we hypothesize that the JIP proteins would be integral for the regulation of LRRK2.
Materials and Methods

Constructs
Wild-type (WT) and mutant LRRK2 V5-His tagged and 2xMyc constructs were generated as described in Greggio et al. [20, 21] . Flag-tagged pcDNA3 JIP1-4 plasmids were generous gifts from Dr. Roger Davis (University of Massachusetts).
Cell Culture HEK293-FT cells were maintained in DEM/10% FBS. Transfections were performed using Lipofectamine 2000 (Invitrogen) as described previously [27, 31] . Coimmunoprecipitation HEK293-FT cells were transfected with the appropriate constructs for 48 h, and coimmunoprecipitations were performed as described previously [27, 32] . Antibodies were purchased from Sigma (V5, Flag, c-myc, actin). Lysates and immunoprecipitates were loaded and resolved by 3-8% NuPAGE Tris-acetate (for studies of JIPs) or 4-20% Tris-glycine gels (for studies of MKK3) for Western blotting.
Subcellular Fractionation
HEK293-FT cells were transfected with the appropriate constructs for 48 h, and subcellular fractionation was performed as described in Hsu et al. [27] to separate the samples into cytosolic and membrane fractions. Antibody against calnexin (Calbiochem) was used as the membrane marker, and antibody against GAPDH (Biodesign) was used as the cytosolic marker. Lysates were loaded and resolved by 3-8% NuPAGE Tris-acetate (for studies of JIPs) or 4-20% Tris-glycine gels (for studies of calnexin and GAPDH) for Western blotting.
Statistical Analysis
All data were expressed as mean 8 SEM and graphed using Prism (GraphPad). One-way ANOVA and Tukey's post-hoc tests were performed to identify statistically significant differences using InStat (GraphPad).
Results
LRRK2 Interacts with MKK3
We have recently shown that LRRK2 binds MKK3, -6 and -7. To confirm these results, we cotransfected HEK-FT 293 cells with WT LRRK2 8 MKK3, and immunoprecipitated the proteins. Figure 1 shows that MKK3 is readily detectable by immunoblot following LRRK2 immunoprecipitation.
LRRK2 Interacts with JIP1-4
The strong association between LRRK2 and MKKs led us to hypothesize that LRRK2 might also interact with the JIPs, and that JIPs might modulate the subcellular translocation of LRRK2 with MKK6. To test this hypothesis, we coexpressed V5His-tagged WT LRRK2 construct with Flag-tagged JIP1-4 constructs in HEK293-FT cells, and performed coimmunoprecipitations to determine whether LRRK2 interacts with the JIPs. 
LRRK2 Increases Levels of JIPs
In related work, we showed that the coexpression of MKK6 with LRRK2 induces the expression and translocation of both proteins from the mitochondria to the plasma membrane and the ER, and that this translocation is dependent upon the functionality of MKK6 [27] . We hypothesize that JIPs may be integral components of the complex regulation of the translocation to the plasma membrane. To test this hypothesis, HEK293-FT cells were transfected with or without JIP1-4, and the lysates were fractionated into cytosolic and membrane fractions. The amounts of JIP1-4 were increased in the presence of LRRK2 in both the cytosolic and the membrane fractions ( fig. 3 ). We did not observe that LRRK2 altered the distribution of the JIPs ( fig. 3 ). These results indicate that expressing LRRK2 increases the steady state levels of JIP proteins, but does not alter the gross distribution of JIPs.
LRRK2 Increases JIP4 Ubiquitination
The ability of LRRK2 to increase levels of JIPs suggests the possibility that LRRK2 modulates degradation of JIPs. To investigate whether LRRK2 modulates the catabolism of JIPs, we investigated whether expressing LRRK2 affects ubiquitination of JIP4. LRRK2 was cotransfected with Flag-tagged JIP4 and HA-tagged ubiquitin. JIP4 was immunoprecipitated and probed with anti-HA antibody to determine whether JIP4 ubiquitination is modified by the presence of WT LRRK2 ( fig. 4 ) . Coexpressing LRRK2 strongly increased ubiquitination of JIP4 ( fig. 4 ) . Immunoblotting for JIP4 also suggested that oligomerization of JIP4 was increased in the presence of LRRK2, although we cannot rule out the possibility that detection of the higher molecular weight species simply reflected elevated levels of JIP4.
JIP4 Oligomerization Is Increased by Disease-Related Mutations in LRRK2
Our previous studies indicate that G2019S and R1441C mutations in LRRK2 exhibit increased binding with MKK6. This observation suggested the possibility that disease-related LRRK2 mutations also enhance binding to JIPs. To explore the effects of disease-related LRRK2 mu- tations on JIP biology, we cotransfected JIP4 with LRRK2 constructs containing mutations linked to disease: G2019S and R1441C, I2020T, Y1699C. The G2019S, R1441C and I2020T mutations were each associated with increased levels of JIP4 and increased levels of oligomerizated complex ( fig. 5 a) . Densitometric quantification indicated that the amount of dimmer was increased for the mutant LRRK2 constructs ( fig. 5 b) , but the apparent increase might also result from the overall increase in total JIP4 levels.
Discussion
Mutations in LRRK2 are among the most common genetic mutations associated with PD. The mechanism by which mutations might contribute to disease is largely unknown, and indeed, the general biology of LRRK2 is poorly understood. In this paper, we set out to understand one aspect of LRRK2 biology evident from its structure. The kinase domain of LRRK2 is homologous to RIP kinases and mixed lineage kinases, which are classes of kinases known to regulate the stress kinase cascades in part through binding to MKKs. We have now shown that LRRK2 also binds to MKKs. We also demonstrate that LRRK2 interacts with a family of scaffold proteins, termed JIPs, which regulate the stress kinase cascades. Cotransfecting LRRK2 increases JIP expression levels, and interaction of LRRK2 with the JIPs might promote their oligomerization, which is thought to be associated with MAPK activation [28] . Most but not all disease-related mutations in LRRK2 that we studied exhibited high-molecular-weight bands indicative of oligomeriza- tion. Interestingly, cotransfecting LRRK2 with JIP4, and possibly other JIPs, also increases levels of ubiquitinated JIP4, although the significance of this change is unclear.
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Our observation that LRRK2 associates with MKKs and with JIPs is consistent with an increasing body of evidence suggesting that LRRK2 regulates the stress kinase cascade. Studies in Caenorhabditis elegans demonstrate that LRRK2 regulates the response to mitochondrial stress (complex I inhibition), and that the response requires the activity of the nematode homologues of MKK6 and p38 [27, 33] . LRRK2 is known to autophosphorylate, although the amount of autophosphorylation is very low. Gloeckner et al. [26] recently demonstrated that LRRK2 can transphosphorylate MKK 3-7 in vitro.
The reaction does not appear to be catalytic, though, because levels of MKK phosphorylation were similar to levels of LRRK2 autophosphorylation, despite addition of more than a 10,000-fold excess of MKK. Phosphorylation of MKK by LRRK2 occurs in the amino-domain, which is far from the sites normally associated with MKK activation [26] . The low level of phosphorylation is consistent with a model in which LRRK2 binds the MKKs, phosphorylates the proteins, but then either does not release the MKK or becomes catalytically inactive. Studies from our laboratory demonstrate that LRRK2 binds to MKKs, but interestingly, we find evidence for phosphorylation of MKKs by LRRK2 in vitro, but not in vivo [27] . Our results suggest that binding of LRRK2 to MKK2 increases the expression and membrane localization of both proteins, as shown by immunocytochemistry and biochemical fractionation.
The interaction of LRRK2 with JIPs is consistent with the observed interaction between LRRK2 and MKKs [27] . JIPs are scaffold proteins for the stress kinase cascade [28] . The ability of LRRK2 to bind JIPs in absence of cotransfected MKKs suggests that LRRK2 binds JIPs directly, or at least through a mechanism that does not require MKKs. Thus, the JIP scaffolding complex appears to contain binding sites for both LRRK2 and MKKs. JIPs function to bring together MKKs with MAPKs (e.g. JNK and p38), and also to direct binding to different sites within the cells. Some JIPs tend to direct binding towards the membrane, such as JIP4, while JIP1-3 are known to bind to microtubules. The interaction of LRRK2 with JIP1-3 suggests that LRRK2 might bind to JIP1-3 as a cargo protein, and that binding might facilitate transport along microtubules. Such transport might be particularly important in neurons where LRRK2 can be found in synaptic fields, such as in the striatum. Other proteins linked to disease also appear to interact with JIPs. ␣ -Synuclein was recently shown to regulate levels of JIP1 [34] . Amyloid precursor protein binds to JIP1 in much the same manner, although the biology of the interaction remains unclear [35] . LRRK2 exhibits a striking ability to increase total levels of JIPs and ubiquitination of JIPs. These two effects in combination suggest that LRRK2 inhibits degradation of JIPs, either through the proteasomal or autophagic systems. Alternatively, LRRK2 might also act to increase JIP translation or transcription. A link between LRRK2 and regulation of protein translation is suggested by the observation that LRRK2 binds and phosphorylates 4E-BP, a regulator of protein translation machinery [24] . A putative role in regulating protein degradation is consistent with the presence of ubiquitin-positive inclusions in most cases of PD that are associated with LRRK2 mutations [5] . Most of these inclusions contain ␣ -synuclein, but some inclusions contain tau protein [5, 36] . The putative ability of LRRK2 to inhibit autophagy or proteasomal function could contribute to increased risk of PD and inclusion formation among subjects with LRRK2 mutations. Several reports also note that LRRK2 overexpression leads to the formation of inclusions containing LRRK2 [20, 37] . Other reports indicate that LRRK2 regulates autophagy [38] . Inhibition of autophagy or proteasomal function could induce inclusion, stimulate inclusion formation as well as increase levels of JIP and JIP oligomers. Further experiments are needed to determine the precise mechanism.
In summary, our data suggest that a strong biological connection exists between LRRK2, the stress kinase cascade and JIPs, a class of scaffold proteins that bind stress kinases. The role of stress kinases in cell death creates a cogent linkage between LRRK2 and cell death. Whether this pathway is the actual pathway linked to the pathophysiology of disease among subjects carrying mutations in LRRK2 remains to be determined. Most of the mutant LRRK2 constructs increased JIP4 levels and oligomerization more than WT with the exception of Y1699C. The incomplete correlation between pathological LRRK2 mutations and enhanced JIP expression/oligomerization suggests that this axis is not the principle mechanism by which LRRK2 causes disease. However, understanding the mechanisms by which LRRK2 modulates the stress kinase cascade could lead to increased understanding of the biology of LRRK2 and potential differences in the pathophysiology of disease among individuals with different LRRK2 mutations.
